U.S. generic drugmaker Mylan Inc is in advanced talks to acquire a multibillion-dollar portfolio of established products from Abbott Laboratories, people familiar with the matter said. The proposed transaction, which is in late-stage discussions, would see Mylan acquire a big chunk of Abbott’s Europe-based mature drugs for several billion dollars, said the people, who asked not to be named because the matter is not public.